Condition category
Infections and Infestations
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
CYP2D6 is an enzyme found in the human body that is involved in the breakdown (metabolism) of drugs such as dextromethorphan. Some people will break down these drugs quickly while others will break them down slowly. These are referred to as different metabolizer phenotypes. If a drug is metabolized too quickly the drug may be less effective, while if the drug is metabolized too slowly there may be harmful side effects. Hence the dose of the drug may have to be adjusted to take into account the speed at which it is metabolized by CYP2D6. This study aims to find out about the possible relationship between CYP2D6 dextromethorphan metabolizer phenotype and the risk of relapse after primaquine treatment against vivax malaria.

Who can participate?
People who participated in the OXTREC 179-12 study (ISRCTN82366390) in Army Batalyon, Sragen, Central Java and who provided informed consent for genetic studies will be tested for the CYP2D6 gene.

What does the study involve?
A single dose of the over-the-counter drug dextromethorphan (DXM) for relieving cough will be given to all 26 relapsing participants and 36 randomly chosen non-relapsing participants. Based on the metabolism of that drug, which occurs exclusively through CYP2D6, we will classify the participants as fast, intermediate, or slow metabolizers.

What are the possible benefits and risks of participating?
The participants will benefit directly by knowing whether they can be successfully treated for the malarial infection or not. The drug being given is a very small dose of a common cough medicine. At this dose we expect few side effects and none being serious. There is a slight risk with taking blood from the veins. The research team will manage all risk.

When is the study starting and how long is it expected to run for?
The study will run from May to June 2014.

Where is the study run from?
This study is collaboration of the Faculty of Medicine, University of Indonesia, and Eijkman Institute for Molecular Biology in Jakarta with Eijkman-Oxford Clinical Research Unit, Jakarta and the Indonesian Army Medical Corps.

Who is funding the study?
Medicine for Malaria Venture (MMV), Switzerland.

Who is the main contact?
Prof Rianto Setiabudy

Trial website

Contact information



Primary contact

Prof Rianto Setiabudy


Contact details

Department of Pharmacology
Faculty of Medicine
University of Indonesia
Jl. Salemba No. 6

Additional identifiers

EudraCT number number

Protocol/serial number

CYP2D6 Phenotyping/EOCRU.2014.001/OXTREC 25-14

Study information

Scientific title

Case-control study of single-dose dextromethorphan CYP2D6 phenotype among patients previously dosed with primaquine and relapsing compared to those not relapsing


Study hypothesis

This study aims to explore the possible relationship between CYP2D6 dextromethorphan metabolizer phenotype and risk of relapse following directly observed primaquine therapy against relapse of vivax malaria.

Ethics approval

1. Medical Research Ethics Committee of Faculty of Medicine, University of Indonesia, 28/04/2014, No. 244/H2.F1/ETIK/2014
2. Oxford Tropical Research Ethics Committee, 01/05/2014, Oxtrec Reference 25-14

Study design

Open-label single-dose single-centre case-control study

Primary study design


Secondary study design

Case-control study

Trial setting


Trial type


Patient information sheet

Not available in web format, please use contact details below to request a patient information sheet




All subjects will be screened up to no more than 10 days prior to study drug administration and fasted overnight (minimum of 8 hours) prior to study drug administration. Subjects will receive a single oral dose of dextromethorphan 30 mg (Kimia Farma Tbk, Bandung, Indonesia) on the morning of Day 0. Serial blood and urine samples will be collected for pharmacokinetic analysis of dextromethorphan (DXM) and dextrorphan, the dextromethorphan metabolite. Subjects will be confined beginning the day prior to dosing (Day 0) and may be discharged from the study unit following the 24-hour procedures. The subjects will be discharged from the study following the completion of all end of study procedures on Day 6 ± 1 day. Total blood volume taken during the study is 120 ml (8 tablespoons).

Intervention type



Not Applicable

Drug names

Primaquine, dextromethorphan

Primary outcome measures

1. Pharmacokinetic parameters such as AUC0-24, AUC0-lqc, AUC0-inf, Cmax and Tmax will be estimated from plasma concentration-time data. Data from subjects prematurely ending participation in the study may be excluded from pharmacokinetic data evaluation
2. Odds ratios (ORs), 95% confidence interval (CI), and P values comparing proportions of CYP2D6 phenotype among relapsing patients compared to those not relapsing will be calculated using the Fisher’s exact test. The CI that included 1 and/or the P values that were >0.05 were considered insignificant

Secondary outcome measures


Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

1. 26 currently healthy subjects of OXTREC 179-12 who experienced a confirmed relapse of vivax malaria following directly observed primaquine therapy will be invited to enroll as cases in the current study
2. 36 currently healthy subjects of OXTREC 179-12 who did not experience a relapse of vivax malaria following directly observed primaquine therapy will be invited to enroll as controls in the current study
3. The subject must be able to read, understand, sign and date the IRB-approved Informed Consent Form for the current study prior to study participation
4. The subject must be judged to be in continued good health as determined by the investigator, based upon the results of a medical history, physical examination, vital signs and clinical laboratory profile
5. The subject must be able to comply with all study procedures including confinement at the investigative site and agree to participate in the entire study, returning for all visits
6. The subject must have normal clinical laboratory test results or, if abnormal, the results are not clinically significant in the investigator’s opinion, at Screening and on Day -1
7. Age 18 years or older, but younger than 65 years

Participant type


Age group




Target number of participants

62 participants (26 relapsers and 36 non-relapsers)

Participant exclusion criteria

1. Subjects who have hypersensitivity to dextromethorphan or related compounds
2. Demonstrate a clinically significant finding from pre-treatment medical history, physical examinations, vital sign measurements, or clinical laboratory tests as determined by the investigator
3. Unwilling or unable to comply with the protocol or reside in the clinical research unit throughout the course of study
4. Has used any excluded medication, supplements or food product outlined in the protocol

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

Department of Pharmacology

Sponsor information


ALERTAsia Foundation (Indonesia)

Sponsor details

Jl. Diponegoro No. 69
+62 (0) 213910414

Sponsor type




Funder type

Research organisation

Funder name

Medicine for Malaria Venture (Switzerland)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes